Rosuvastatin pre-treatment in patients undergoing elective PCI to reduce the incidence of myocardial periprocedural necrosis. The ROMA trial

Catheterization and Cardiovascular Interventions, 04/30/2012

High loading dose of Rosuvastatin within 24 hours before elective percutaneous coronary intervention (PCI) seems to decrease the incidence of periprocedural myocardial necrosis during a period of 12–months compared to the standard treatment.

Methods

  • 160 patients with stable angina who underwent elective PCI were randomly assigned to receive either a pre–procedural loading dose (40 mg) of Rosuvastatin (RG n=80) or a standard treatment (CG n=80).
  • The primary end–point was the incidence of periprocedural myocardial necrosis.
  • The secondary end–point was the assessment of MACCE (cardiac death, all–MI,stroke and TVR) at a 30–day and 12–month follow–up, as well as the rate of periprocedural rise of Troponin T serum levels> 3xULN.

Results

  • Twelve and 24–hour post–PCI CK–MB elevation>3x occurred more frequently in the CG than in the RG (22.7 vs 7.1;p=0.034 and 26.4 vs 8.7;p=0.003).
  • At the 30–day and 12–month follow–up the incidence of cumulative MACCEwas higher in CG than in the RG (30.0% vs 8.7%; p=0.001 and 35.0% vs 12.5%;p=0.001).
  • The difference between the groups was mainly due to the periprocedural MI incidence (26.4% vs 8.7%;p=0.003).
  • The rate of cardiac death, spontaneous MI, TVR and stroke were similar in the two groups.

Print Article Summary

The Top Read Articles of 2014 are Now Available

Scouring thousands of peer-reviewed journals and popular press, Our Editors just released the Top Read Articles of the Year. See the Top Read List